FI59596C - Foerfarande foer framstaellning av en terapeutiskt anvaendbar 7-(3-oxobutyl)-1,3-di-(n-butyl)xantin - Google Patents

Foerfarande foer framstaellning av en terapeutiskt anvaendbar 7-(3-oxobutyl)-1,3-di-(n-butyl)xantin Download PDF

Info

Publication number
FI59596C
FI59596C FI750122A FI750122A FI59596C FI 59596 C FI59596 C FI 59596C FI 750122 A FI750122 A FI 750122A FI 750122 A FI750122 A FI 750122A FI 59596 C FI59596 C FI 59596C
Authority
FI
Finland
Prior art keywords
butyl
oxobutyl
xanthine
therapeutic
effect
Prior art date
Application number
FI750122A
Other languages
English (en)
Finnish (fi)
Other versions
FI750122A (US06262066-20010717-C00315.png
FI59596B (fi
Inventor
Guenther Brenner
Joachim Goering
Eskendar Ali Kahn
Oskar Rohte
Manfred Tauscher
Original Assignee
Wuelfing J A Fa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2402908A external-priority patent/DE2402908C2/de
Application filed by Wuelfing J A Fa filed Critical Wuelfing J A Fa
Publication of FI750122A publication Critical patent/FI750122A/fi
Priority to FI801875A priority Critical patent/FI801875A/fi
Application granted granted Critical
Publication of FI59596B publication Critical patent/FI59596B/fi
Publication of FI59596C publication Critical patent/FI59596C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI750122A 1974-01-22 1975-01-20 Foerfarande foer framstaellning av en terapeutiskt anvaendbar 7-(3-oxobutyl)-1,3-di-(n-butyl)xantin FI59596C (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI801875A FI801875A (fi) 1974-01-22 1980-06-11 7-(oxoalkyl)-1,3-dialkylxantiner foerfarande foer deras framstaellning och laekemedel innehaollande dessa foereningar

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2402908 1974-01-22
DE2402908A DE2402908C2 (de) 1974-01-22 1974-01-22 7-(3-Oxobutyl)-1,3-di-(n-butyl)-xanthin und Verfahren zu seiner Herstellung

Publications (3)

Publication Number Publication Date
FI750122A FI750122A (US06262066-20010717-C00315.png) 1975-07-23
FI59596B FI59596B (fi) 1981-05-29
FI59596C true FI59596C (fi) 1981-09-10

Family

ID=5905372

Family Applications (1)

Application Number Title Priority Date Filing Date
FI750122A FI59596C (fi) 1974-01-22 1975-01-20 Foerfarande foer framstaellning av en terapeutiskt anvaendbar 7-(3-oxobutyl)-1,3-di-(n-butyl)xantin

Country Status (13)

Country Link
US (2) US4242345A (US06262066-20010717-C00315.png)
JP (1) JPS5912677B2 (US06262066-20010717-C00315.png)
AR (1) AR207462A1 (US06262066-20010717-C00315.png)
AT (1) AT338286B (US06262066-20010717-C00315.png)
BE (1) BE824665A (US06262066-20010717-C00315.png)
CA (1) CA1068693A (US06262066-20010717-C00315.png)
CH (1) CH608236A5 (US06262066-20010717-C00315.png)
FI (1) FI59596C (US06262066-20010717-C00315.png)
FR (1) FR2258183B1 (US06262066-20010717-C00315.png)
GB (1) GB1441562A (US06262066-20010717-C00315.png)
HU (1) HU169012B (US06262066-20010717-C00315.png)
NL (1) NL184330C (US06262066-20010717-C00315.png)
YU (1) YU15175A (US06262066-20010717-C00315.png)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2507554A1 (de) * 1975-02-21 1976-09-02 Wuelfing J A Fa 7-(oxoalkyl)-1,3-dialkylxanthine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE2507555A1 (de) * 1975-02-21 1976-09-02 Wuelfing J A Fa 7-(oxoalkyl)-1,3-dialkylxanthine, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel
EP0005015B1 (en) * 1978-04-22 1986-10-29 BEECHAM - WUELFING GmbH & Co. KG Use of a xanthine derivate in the manufacture of a medicament
IL59665A0 (en) * 1979-04-05 1980-06-30 Wuelfing J Kg Xanthine derivatives,process for their preparation and their use in pharmaceutical compositions
DE3173289D1 (en) * 1980-06-21 1986-02-06 Beecham Wuelfing Gmbh & Co Kg Xanthine derivatives, pharmaceutical compositions containing them and a process for their preparation
GB8418430D0 (en) * 1984-07-19 1984-08-22 Beecham Wuelfing Gmbh & Co Kg Treatment
JPS63225317A (ja) * 1986-10-06 1988-09-20 Hoechst Japan Kk 抗消化性潰瘍剤
US5096906A (en) * 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
JP2661666B2 (ja) * 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 抗消化性潰瘍剤
US5321029A (en) * 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
CA2030112A1 (en) * 1989-11-24 1991-05-25 Yasuo Ito Xanthine compound, method for preparing thereof, and a pharmaceutical composition comprising the same
DE69119700T2 (de) * 1990-11-07 1996-11-07 Hoechst Roussel Pharma Verwendung von Xanthinen zur Herstellung von Arzneimitteln zur Hemmung der Vermehrung menschlicher Retroviren
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
MX9203323A (es) * 1991-07-11 1994-07-29 Hoechst Ag El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales.
TW288977B (US06262066-20010717-C00315.png) * 1992-02-22 1996-10-21 Hoechst Ag
EP0570831A2 (de) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
EP1434782A2 (en) * 2001-10-01 2004-07-07 University of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
SG155182A1 (en) * 2004-08-02 2009-09-30 Univ Virginia 2-propynyl adenosine analogs with modified 5æ-ribose groups having a2a agonist activity
WO2006023272A1 (en) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA557342A (en) 1958-05-13 Doebel Karl Process for the manufacture of novel xanthine derivatives
US2756229A (en) * 1956-07-24 Xanthine derivatives
US2761863A (en) * 1956-09-04 Lower-alkyl
FR4791E (fr) 1900-06-29 1905-10-16 Eugene Fournier Lampe à pétrole perfectionnée pour chauffage intensif dite: "la naphteuse"
DE926788C (de) 1952-11-07 1955-04-25 Geigy Ag J R Verfahren zur Herstellung von 1, 3-dialkylierten 7-Oxyalkyl-xanthinabkoemmlingen
GB759174A (en) * 1952-11-07 1956-10-17 Geigy Ag J R Improvements in diuretic acting xanthine derivatives
GB759981A (en) * 1953-09-09 1956-10-24 Roche Products Ltd Process for the manufacture of xanthine derivatives
CH325292A (de) 1953-10-21 1957-10-31 Geigy Ag J R Verfahren zur Herstellung von 7-Oxyalkyl-xanthinderivaten
US3737433A (en) * 1964-09-05 1973-06-05 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines
DE2234202A1 (de) 1972-07-12 1974-01-24 Albert Ag Chem Werke Verfahren zur herstellung von oxoalkylxanthinen
DE2330742C2 (de) 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2457666A1 (de) * 1974-12-06 1976-06-10 Hoechst Ag Arzneimittel, verfahren zur herstellung von dafuer geeigneten wirkstoffen und diese oxoalkyl-dialkyl-xanthine
JPS5233120A (en) * 1975-09-10 1977-03-14 Nisshin Steel Co Ltd Double coiled automobile steel pipe covered with heat flexible plastic resin

Also Published As

Publication number Publication date
GB1441562A (en) 1976-07-07
FI750122A (US06262066-20010717-C00315.png) 1975-07-23
CA1068693A (en) 1979-12-25
US4291037A (en) 1981-09-22
NL7414887A (nl) 1975-07-24
HU169012B (US06262066-20010717-C00315.png) 1976-08-28
BE824665A (fr) 1975-05-15
FR2258183B1 (US06262066-20010717-C00315.png) 1978-07-28
FR2258183A1 (US06262066-20010717-C00315.png) 1975-08-18
JPS5912677B2 (ja) 1984-03-24
FI59596B (fi) 1981-05-29
NL184330B (nl) 1989-01-16
ATA929674A (de) 1976-12-15
AT338286B (de) 1977-08-10
JPS50101386A (US06262066-20010717-C00315.png) 1975-08-11
YU15175A (en) 1982-06-30
NL184330C (nl) 1989-06-16
CH608236A5 (US06262066-20010717-C00315.png) 1978-12-29
US4242345A (en) 1980-12-30
AR207462A1 (es) 1976-10-08

Similar Documents

Publication Publication Date Title
FI59596C (fi) Foerfarande foer framstaellning av en terapeutiskt anvaendbar 7-(3-oxobutyl)-1,3-di-(n-butyl)xantin
Hagelberg et al. Toxicokinetics of ochratoxin A in several species and its plasma‐binding properties
PL136579B1 (en) Process for preparing derivatives of 2-propoxymethylguanine
JPS6146455B2 (US06262066-20010717-C00315.png)
CN101675927A (zh) 治疗分子及方法-1
JP2023517541A (ja) 不整脈の治療のためのニコチンアミドモノヌクレオチド誘導体
CA2454654A1 (en) Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
JP2865255B2 (ja) １，２，３，４，１０，１４ｂ‐ヘキサヒドロジベンゾ〔ｃ，ｆ〕ピラジノ〔１，２‐ａ〕アゼピノ誘導体及び１０‐アザ，１０‐オキサ及び１０‐チア類似体
Fisher et al. Influence of alkylating agents on kidney erythropoietin production
EP2542232A2 (en) Fatty acid inhibitors
FI59250C (fi) Foerfarande foer framstaellning av cancerostatiskt och immunstimulerande verkande 4-imino-1,3-diazabicyklo-(3,1,0)-hexan-2-on
FI62089C (fi) Foerfarande foer framstaellning av pao det perifera blodomloppet verkande 7-(n-(3-fenoxi-2-hydroxipropyl)-n-amino)-1,3-dialkyl-xantinderivat
GB1570158A (en) Immunosuppressant substituted glutamine formulations
CN102617679B (zh) 一种共轭亚油酸与吉西他滨连接的前体药物制备方法及其应用
SU1347865A3 (ru) Способ получени производных триазолопиримидина или их солей с метансульфокислотой
CN114588161A (zh) 具有防治肺炎作用的次黄碱衍生物
CN107513055B (zh) 一种利巴韦林衍生化合物及其药物组合物
CN106038562A (zh) 一种治疗类风湿性关节炎的药物
CN115477655B (zh) 与肿瘤坏死因子-α对接的二氧六环-四氢咔啉-3-甲酰氨基酸的制备和应用
CN1398183A (zh) 含铂络合物化合物的药物和其用途
PT90560B (pt) Processo para a preparacao de uma composicao farmaceutica contendo o derivado de tiazol acido 2-(3-carboxi-1-propiltio)-4-metil-1,3-tiazolil-5-acetico(tiprotimod) para terapia de infeccoes por virus
Mortimer The toxic effects of sporidesmin on mice
AU2004298907A1 (en) Use of a compound having two gold (I) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold (I) atoms for the treatment of cancer
JPS5885818A (ja) 新規なイミダゾールカルボン酸誘導体を含む心不全治療剤
DE2107936C3 (de) Alkylsulfonsäureester von 2-Oxo-13,2-oxazaphosphorinanen und diese enthaltende pharmazeutische Präparate

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: WUELFING, JOHANN A.